The Influence of Geography, Time, and Payer Type on the Utilization of Bone Morphogenetic Protein (BMP) Between 2005 and 2015.
Bone morphogenetic protein (BMP) is a critical compound for endochondral bone formation and is used as a bone graft substitute to promote spinal fusion and fracture healing. We sought to identify rate, type, and applications of use of BMP in spinal fusion surgery during 2005 to 2015. The Medicare 5% national sample (SAF5) database and the Humana Orthopaedics database (HORTHO) were searched for patients who underwent spinal fusion with BMP. Rate of use over time and influence of geographic region and payer type on utilization of BMP during 2005 to 2015 were analyzed. A total of 9879 and 12,598 patients were treated with BMP within the SAF5 database and HORTHO databases, respectively. There was a statistically significant variation in use of BMP among geographic regions. Rate of BMP usage for patients above 65 years old was 11.02 and 58.91 patients per 100,000 members for SAF5 and HORTHO databases, respectively (P<0.001). Rate of use of BMP did not vary significantly during 2005 to 2012 within the SAF5 database (P=0.153). There was a trend toward lower use of BMP in the HORTHO database between 2007 and 2015 (P=0.081). BMP use was higher for private pay than Medicare.